- Cbl‑b is a member of the CBL family of single‑chain RING finger ubiquitin ligases, alongside c‑Cbl and Cbl‑c. While all three paralogues share a conserved structural framework, Cbl‑b has evolved a highly specialised role in the immune system, where it acts as a central regulator of lymphocyte activation, immune tolerance and inflammatory signalling. Its ability to restrain excessive immune responses makes Cbl‑b essential for maintaining immune homeostasis and preventing autoimmunity.
- Structurally, Cbl‑b contains the hallmark TKB (tyrosine kinase‑binding) domain, which recognises phosphorylated tyrosine residues on activated receptors and signalling intermediates. Adjacent to this is the RING finger domain, a zinc‑binding module that interacts with ubiquitin‑charged E2 enzymes (E2~Ub). Through this domain, Cbl‑b catalyses direct ubiquitin transfer to its substrates, marking them for degradation, trafficking or signalling modulation. The C‑terminal region of Cbl‑b contains proline‑rich motifs and regulatory sequences that enable interactions with adaptor proteins involved in immune signalling.
- Functionally, Cbl‑b is indispensable for controlling T‑cell activation. It sets the activation threshold by ubiquitinating key signalling molecules such as PI3K, PLC‑γ1 and components of the CD28 co‑stimulatory pathway. In the absence of Cbl‑b, T‑cells become hyperresponsive, proliferating vigorously even in the presence of weak antigenic stimulation. This hyperactivity leads to breakdown of immune tolerance, spontaneous autoimmunity and heightened inflammatory responses. Cbl‑b also regulates B‑cell receptor signalling, NK‑cell cytotoxicity, and dendritic cell activation, making it a broad regulator of adaptive and innate immunity.
- The importance of Cbl‑b in immune regulation is highlighted by studies showing that Cbl‑b‑deficient mice develop autoimmune diseases, including systemic inflammation and organ‑specific autoimmunity. Their T‑cells exhibit enhanced IL‑2 production, increased proliferation and resistance to anergy. Interestingly, this hyperactive immune phenotype also results in strong anti‑tumour immunity, as Cbl‑b‑deficient T‑cells and NK cells display heightened cytotoxic activity against cancer cells. This has made Cbl‑b an attractive target in cancer immunotherapy, where pharmacological inhibition of Cbl‑b could potentially boost immune responses against tumours.
- Beyond lymphocytes, Cbl‑b influences signalling pathways downstream of receptor tyrosine kinases, although to a lesser extent than c‑Cbl. It modulates pathways involving Akt, NF‑κB and MAP kinases, integrating signals from immune receptors and cytokines. Its ability to fine‑tune signalling ensures that immune responses are strong enough to eliminate pathogens but restrained enough to avoid damaging host tissues.
- Clinically, dysregulation of Cbl‑b has been linked to autoimmune disorders, chronic inflammation and altered responses to infections. Genetic variations in the CBLB gene have been associated with susceptibility to diseases such as type 1 diabetes, multiple sclerosis and systemic lupus erythematosus. Because of its central role in immune tolerance, Cbl‑b is being explored as a biomarker for immune dysfunction and as a therapeutic target in both autoimmunity and oncology.
- In summary, Cbl‑b is a specialised RING finger ubiquitin ligase that acts as a master regulator of immune activation. By controlling the strength and duration of signalling in T‑cells, B‑cells and NK cells, it maintains immune balance and prevents pathological inflammation. Its unique role in immune tolerance and anti‑tumour immunity makes Cbl‑b a compelling focus for future therapeutic strategies aimed at modulating immune responses in disease.
